Creatine and Mood: What 2025 Research Reveals

Creatine is widely recognized as a performance supplement for athletes, but a fast-moving body of emerging, peer-reviewed research is examining a surprising second frontier: its potential role in supporting mood and everyday wellbeing. Systematic reviews published in 2025 and a 2026 meta-analysis of randomized controlled trials have added significant nuance to this question — and the findings are worth understanding carefully for anyone interested in the intersection of brain energy metabolism and mental health. This article unpacks the current evidence, the proposed mechanisms, the populations most likely to benefit, and the honest limitations of what we know so far.

The Brain Energy Deficit Hypothesis

Mood is not simply a matter of serotonin. Neuroscientists have increasingly focused on a complementary mechanism: energy supply in prefrontal and limbic brain regions. Neurons are among the most metabolically demanding cells in the body, and shifts in mitochondrial function and high-energy phosphate availability have been measured via phosphorus-31 magnetic resonance spectroscopy (31P-MRS).

Creatine sits at the center of cellular energy buffering. In the brain, creatine combines with inorganic phosphate via the enzyme creatine kinase to regenerate adenosine triphosphate (ATP) from adenosine diphosphate (ADP) — the phosphocreatine shuttle. This system is particularly critical during periods of high neuronal firing: exactly the kind of sustained metabolic activity required for mood regulation, executive function, and stress response. When brain creatine stores are depleted, this buffer loses capacity, and neuronal performance degrades under metabolic load.

Studies using 31P-MRS have found lower phosphocreatine levels in the frontal lobes of some people with persistently low mood, providing a mechanistic rationale for why creatine supplementation is being studied for its role in supporting neuronal resilience. A 2024 review published in Nutrients (PMC11567172) mapped this framework comprehensively, tracing creatine's intersections with BDNF signaling, neuroplasticity, and serotonergic function.

What Clinical Trials Show: A 2025–2026 Evidence Update

The evidence base for creatine and mood has matured considerably in the past two years. A 2026 systematic review indexed in PubMed Central (PMC12823350) synthesized six articles from five randomized controlled trials (RCTs) involving 238 participants. Key findings from that synthesis:

• Creatine supplementation consistently outperformed placebo on standardized mood rating scales across the majority of included trials.
• Mean participant age was 36 years; only 26% were male, indicating that most evidence to date comes from female participants.

A separate 2025 meta-analysis in the British Journal of Nutrition (Cambridge Core) found an average improvement of approximately 2.2 points on a standard 17-item clinical mood rating scale (HDRS-17). The minimum clinically important difference on this scale is 3.0 points, so the average effect fell just below the threshold for clinical significance — a distinction worth noting for interpreting aggregate results versus individual trial outcomes.

The honest takeaway from the current literature: creatine shows a statistically significant effect on mood scores in most trials, but the average effect size at standard doses may be modest on its own.

How Creatine May Support Brain Chemistry

The proposed mechanism: creatine supports the ATP-dependent processes that enable serotonin synthesis, vesicular packaging, and receptor signal transduction. A 2025 review in Frontiers in Psychiatry (Frontiers Psychiatry) elaborated on this, noting that creatine also appears to modulate NMDA receptor function and support GABAergic balance — pathways relevant to mood and the stress response.

Creatine may also help the brain cope with inflammation. Elevated pro-inflammatory cytokines (including IL-6 and TNF-α) are known to suppress mitochondrial function. Creatine's role as an energy buffer may partially offset this suppression, preserving synaptic plasticity even under conditions of chronic low-grade neuroinflammation.

Dosing Protocols in the Research Literature

Understanding what doses the research actually used matters for interpreting the results properly. The following table summarizes the dosing landscape across published trials:

1. 2–5 g/day (standard range): Most RCTs have used this range for 4–8 weeks. This aligns with maintenance dosing commonly used in sports science and is generally well tolerated.
2. 5–10 g/day (higher-dose protocols): Some trials used higher doses, particularly in cases where 31P-MRS confirmed reduced baseline brain creatine levels.
3. Duration: Trials with the most significant effects ran at least 6–8 weeks — consistent with the time needed for brain creatine concentrations to meaningfully elevate, given that the blood-brain barrier limits the rate of central creatine accumulation relative to muscle uptake.

All published RCTs have used creatine, the most extensively studied form. A 5g dose reliably elevates plasma creatine and promotes tissue uptake over time. Brain accumulation is slower than in skeletal muscle, which may explain why mood-related effects tend to emerge over weeks rather than days.

Which Populations Show the Strongest Signal?

Not everyone is equally likely to respond to creatine for mood. Based on the current evidence, several subgroups stand out:

• Vegans and vegetarians: Dietary creatine comes almost entirely from meat and fish. Plant-based individuals have lower baseline muscle and brain creatine stores and may experience larger absolute gains from supplementation — and a correspondingly stronger effect on outcomes tied to creatine availability.
• Women: The RCT literature has disproportionately enrolled women. Some researchers hypothesize this reflects a genuine biological difference: estrogen modulates creatine transporter expression, and women may rely more heavily on dietary creatine to maintain brain creatine homeostasis.
• People who feel low on energy: Creatine's effects on both peripheral muscle energetics and central fatigue may make it particularly relevant for people whose low mood comes with brain fog or prominent energy depletion.

Honest Limitations and What the Research Still Needs

The science is promising but not settled. Several limitations should temper overly strong conclusions from the current evidence base:

• Small aggregate sample sizes: The 2026 systematic review included only 238 participants across five trials. This limits statistical power and generalizability to broader populations.
• Heterogeneous study populations: Trials vary in baseline mood scores, medication background, and duration, making head-to-head comparisons difficult.
• Potential publication bias: Most published trials show positive results; null findings may be underreported, a common limitation in nutritional psychiatry research.
• Mechanistic confirmation gap: While the phosphocreatine/ATP model is biologically compelling, it is difficult to confirm that brain creatine levels actually increase meaningfully at doses used in most studies without concurrent 31P-MRS monitoring.
• Talk to your doctor first: The 2026 systematic review noted isolated reports of manic episodes in some participants supplementing with creatine, so anyone with a history of mood-related health conditions should check with their physician before starting.

Active research directions include larger adequately powered RCTs, neuroimaging-stratified trials that enroll participants with confirmed brain energy deficits at baseline, and dose-escalation studies. The field is evolving rapidly, and several larger registered trials are expected to report results by 2027.

Key Takeaways for the Research-Minded Reader

Creatine supplementation is not a replacement for professional mental health care, and nothing in this article should be read as clinical advice. What the current data do support is a plausible, mechanistically grounded rationale for creatine as a supporting player for mood — particularly at 5g/day over at least 6–8 weeks. For vegans and women, the biological rationale and research signal are both stronger than for the general population. Anyone considering creatine for mood support should discuss it with their physician before starting.